TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05790486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a Break plus Nicotine replacement therapy (NRT) Sampling
Description: Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Comparison
Description: The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Paramedicine Standard Plus Enhanced Implementation Program
Description: Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Paramedicine Standard Implementation Program
Description: In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
Study: NCT05199584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV-101 (taladegib)
Description: tablets dosed once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV-101 (taladegib)
Description: tablets dosed once-daily
Study: NCT06294600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Oral tablets of 500mg of clarithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tablets
Description: Oral tablets of similar appearance to active study drug
Study: NCT05782647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartGuide cuffless BP monitor
Description: Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
Study: NCT05786157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
Study: NCT05877144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve-Sparing Prostatectomy
Description: Undergo nerve-sparing prostatectomy per standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Receive LiSWT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duplex Ultrasound
Description: Undergo DDUS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Nerve-Sparing Prostatectomy
Description: Undergo nerve-sparing prostatectomy per standard of care

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Receive sham LiSWT

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Duplex Ultrasound
Description: Undergo DDUS

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04640714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONTINUity of care Under Management by Video visits (CONTINUUM-V)
Description: Video visit by nurse practitioner within 3 business days of hospital discharge.
Study: NCT05192343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality and nature sounds
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature sounds
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes.
Study: NCT05313438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPNS Therapy
Description: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
Study: NCT05782647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartGuide cuffless BP monitor
Description: Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
Study: NCT05284201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFT System
Description: The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
Study: NCT05173584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
Study: NCT05051462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family / systemic constellation therapy
Description: Family / systemic constellation therapy is a short-term group counseling intervention aiming to help clients better understand and resolve their conflicts within their personal systems, which in turn might lead to a decrease in psychopathological or functional somatic symptoms. The personal system addressed is most often the family but other inter- or intrapersonal systems (e.g., ego parts, victim-perpetrator dyads) can also be the target of the intervention.
Study: NCT06121245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton Pump inhibitor
Description: A proton pump inhibitor will be used as a tool to study the effect of pH changes in the stomach lumen on the release of somatostatin (evaluated by measurements of somatostatin and pro-somatostatin 1-64)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06343090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell
Description: Murine-derived CD19 CAR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell
Description: Murine-derived CD19 CAR T cells
Study: NCT05119270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser assisted cataract surgery with Active Sentry handpiece
Description: The LenSx laser (Alcon Laboratories Inc., USA) automates key steps in the procedure including capsulorhexis, incision making and phaco. The Frequency Domain - Optical Coherence Tomography (FD-OCT) optical imaging system provides high-resolution, real-time visualization of ocular structures and their dimensions. The device sends the results to the interface which programs the laser and indicates the exact location, size and depth of the desired incisions.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard phacoemulsification with the Active Sentry handpiece
Description: Phacoemulsification is done by using the Active Sentry handpiece to allow for a better control of the intraocular pressure throughout the surgery.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium.
Study: NCT06343090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR T cells
Description: humanized CD22 CAR T cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem-cell transplantation
Description: allo-HSCT
Study: NCT05119270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard phacoemulsification with the OZil handpiece
Description: Phacoemulsification is done by using the traditional OZil handpiece that allows rotational movement of the phaco tip.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium.
Study: NCT05117918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUFU Clinical Care Pathway for Overactive Bladder
Description: Treatment of OAB via the SUFU clinical care pathway

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SUFU Clinical Care Pathway for Overactive Bladder
Description: Treatment of OAB via the SUFU clinical care pathway

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Delivery of care via telemedicine
Study: NCT04668261

Intervention type: OTHER
Intervention: Advanced imaging investigation
Description: MRI imaging

Intervention type: OTHER
Intervention: Advanced imaging investigation
Description: MRI imaging
Study: NCT04678687

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver, lung, heart and kidney biopsy
Description: Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
Study: NCT06022471

Intervention type: PROCEDURE
Intervention: Stapes surgery
Description: Stapedectomy operation
Study: NCT05383924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postplacental IUD insertion
Description: patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed IUD insertion
Description: cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
Study: NCT05213273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional guidelines to promote healthy diet and increase fish intake
Description: Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish.
Study: NCT06154902

Intervention type: DRUG
Intervention: Idecabtagene vicleucel
Description: According to approved product label in France

Intervention type: OTHER
Intervention: Not treated
Description: Eligible for idecabtagene vicleucel treatment but not treated
Study: NCT06002230

Intervention type: DRUG
Intervention: Homeopathic medicines
Description: Globules were administered orally..
Study: NCT05548647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Treatment
Description: All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh \< 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
Study: NCT06544109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
Study: NCT05548647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Treatment
Description: All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh \< 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An inactive saline solution administered via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Description: Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
Study: NCT05567965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home care intervention
Description: The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home care intervention
Description: The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
Study: NCT05531422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled fentanyl aerosol
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Study: NCT06543628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: Participants will take tadalafil once daily at a dose of 5 mg for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Description: Participants will take tadalafil once daily at a dose of 5 mg for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPUS (Low Intensity Pulsed Ultrasound)
Description: Participants will receive LIPUS treatment applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
Study: NCT05380024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225mg QD 8 weeks
Study: NCT04704505

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radium-223
Description: Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bipolar Androgen Therapy (BAT)
Description: All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
Study: NCT05207280

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Noradrenaline plus Terlipressin
Description: Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Noradrenaline plus Terlipressin
Description: Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock
Study: NCT04807374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control IQ
Description: We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
Study: NCT04753125

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: follow-up by telephone
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: follow-up by telephone
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: follow-up by telephone
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: follow-up via a game in a smartphone app
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: follow-up via a game in a smartphone app
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: follow-up via a game in a smartphone app
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional follow-up by a health professional
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional follow-up by a health professional
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: conventional follow-up by a health professional
Description: The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance